Psoriasis Scalp Treatment Liquid
NDC 83004-026
Product Information
Psoriasis Scalp Treatment (salicylic acid) is a OTC MONOGRAPH DRUG-approved product labeled by Rida Llc. This medication is used on the skin to treat common skin and foot (plantar) warts. It is supplied as a liquid for topical administration. This product entry covers the primary NDC 83004-026 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 83004-026?
What are the uses of this product?
What are Active Ingredients of this product?
- SALICYLIC ACID 3 g/100mL - A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SALICYLIC ACID (UNII: O414PZ4LPZ)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
- SODIUM C14-16 OLEFIN SULFONATE (UNII: O9W3D3YF5U)
- COCAMIDOPROPYL BETAINE (UNII: 5OCF3O11KX)
- PEG-120 METHYL GLUCOSE DIOLEATE (UNII: YM0K64F20V)
- POLYQUATERNIUM-7 (UNII: 0L414VCS5Y)
- TROLAMINE (UNII: 9O3K93S3TK)
- PANTHENOL (UNII: WV9CM0O67Z)
- .ALPHA.-TOCOPHEROL ACETATE (UNII: 9E8X80D2L0)
- TEA TREE OIL (UNII: VIF565UC2G)
- GREEN TEA LEAF (UNII: W2ZU1RY8B0)
- ASCORBIC ACID (UNII: PQ6CK8PD0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2707560 - salicylic acid 3 % Topical Spray
- RxCUI: 2707560 - salicylic acid 30 MG/ML Topical Spray
* Please review the full disclaimer at the bottom of this page.